# Gallup Finds Cannabis Smoking at a Record High in 2026 > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/gallup-cannabis-smoking-record-high-2026/ > **Published:** 2026-08-24T09:33:16-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:46:58-04:00 > **Clinical Summary:** The Gallup cannabis smoking poll found 17% of U.S. adults report smoking marijuana. CED explains the limits and clinical meaning. --- CED Clinical Relevance #86 High [Public Health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) and Clinical Relevance A new national Gallup survey measures smoking and edible use, identifies demographic differences, and places cannabis alongside declining cigarette use. Clinical Insight | CED Clinic Gallup’s July 2026 national survey found that 17% of U.S. adults said they smoke marijuana, tying the organization’s 2023 high, while 15% said they consume marijuana edibles. The poll describes self-reported behavior, not dose, frequency, medical purpose, impairment, product potency, or health outcomes. For clinicians, the useful implication is not that cannabis has become safer or more dangerous. It is that routine history-taking should distinguish smoking, vaping, edibles, dose, frequency, reason for use, tobacco co-use, and functional effects rather than relying on a single yes-or-no cannabis question. Gallup PollCannabis SmokingEdibles[Public Health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/)Clinical Counseling Audience Patients, families, clinicians, public-health readers, policymakers, and cautious readers interpreting national cannabis-use trends. Primary Topic Gallup’s July 2026 national survey of self-reported marijuana smoking, edible use, cigarette smoking, vaping, and nicotine-pouch use. Source [Read the Gallup survey report](https://news.gallup.com/poll/713645/marijuana-smoking-record-high-cigarettes-low.aspx) Seventeen percent of U.S. adults told Gallup they smoke marijuana, tying a record high, but the poll cannot measure dose, impairment, dependence, or medical benefit. What This Study Teaches Us Population surveys can show how common a reported behavior is and how it varies across groups. They cannot determine whether an individual’s use is therapeutic, recreational, low risk, harmful, occasional, or frequent without more detailed questions. Why This Matters Cannabis smoking is no longer a marginal behavior in national polling. That makes route-specific counseling, respiratory screening, product literacy, and nonjudgmental assessment increasingly relevant in ordinary clinical care. Study Snapshot Source Gallup Consumption Habits poll Interview dates July 1 to July 19, 2026 Publication date August 24, 2026 Sample 1,200 U.S. adults age 18 and older Coverage All 50 states and the District of Columbia Method Random-digit-dial telephone interviews conducted by ReconMR Sampling error Plus or minus 4.0 percentage points for the total sample at 95% confidence Marijuana smoking 17%, tied with Gallup’s 2023 high Marijuana edibles 15%, compared with 14% in 2022 and 12% in 2024 Cigarette smoking 11%, tied with Gallup’s record low Evidence type Cross-sectional public-opinion survey Clinical evidence None; the poll does not measure health outcomes Clinical Bottom Line The poll supports better route-specific screening and counseling, not conclusions about an individual’s dose, diagnosis, benefit, impairment, or risk. Opening News Brief Gallup reported on August 24 that 17% of U.S. adults say they smoke marijuana, tying the organization’s 2023 record. Fifteen percent say they consume marijuana edibles, while 11% report smoking cigarettes. The poll used telephone interviews with 1,200 adults from July 1 through July 19. Gallup reports a plus or minus 4.0 percentage-point sampling margin for the full sample, and notes that wording and practical survey difficulties can introduce additional error. For Patients and Families The national estimate does not define whether a person’s [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) is safe, medically appropriate, or problematic. Route, amount, potency, timing, other substances, health conditions, and functional effects matter more for an individual decision. People who smoke cannabis should discuss cough, wheeze, breathlessness, asthma, tobacco use, and alternative routes with a clinician. Edibles avoid smoke but introduce delayed effects and dosing challenges, so they are not automatically risk free. For Clinicians A binary cannabis question misses the distinction highlighted by the poll. Ask separately about smoking, vaping, edibles, concentrates, tinctures, dose, frequency, medical purpose, tobacco co-use, and adverse effects. Screening should remain nonjudgmental and clinically proportionate. Population prevalence does not diagnose [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/), but increasing normalization makes it easier to overlook tolerance, withdrawal, impaired control, unsafe driving, psychiatric vulnerability, or respiratory symptoms. How This Fits the Bigger Picture Gallup first asked its current marijuana-smoking question in 2013, when 7% answered yes. The 2026 estimate is more than double that figure, while cigarette smoking has moved in the opposite direction over decades. The trends reflect changing behavior and social context, but the poll cannot identify why they changed. Legal access, perceived risk, generational replacement, medical use, product availability, tobacco control, and survey disclosure may all contribute. What This Does Not Show The poll does not measure dose, potency, frequency, impairment, dependence, respiratory disease, medical benefit, or reasons for use. It does not establish that marijuana smoking caused cigarette use to fall. Smoking and edible percentages may overlap because respondents could report both. Adding 17% and 15% would therefore overstate the share of adults who use cannabis. Key Clinical Caveats Combustion exposes the respiratory tract to smoke and irritants. Oral products avoid combustion but have slower onset, longer duration, and greater risk of accidental overconsumption when users redose too soon. Extra caution is appropriate around driving, pregnancy, adolescence, psychosis vulnerability, cardiovascular symptoms, sedating combinations, child access, and jobs that involve safety-sensitive tasks. Where It Deserves Skepticism Record high is a trend label, not proof of a statistically meaningful increase from every recent year. The 17% result ties 2023 and sits within a survey margin of error. Telephone self-report can be affected by nonresponse, disclosure, memory, and interpretation of the word smoke. Subgroup percentages have wider uncertainty than the total-sample estimate. Policy and [Public Health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) Angle Public-health surveillance should distinguish route, frequency, medical purpose, co-use, product potency, and impairment. A single smoking question is useful for a trend line but too coarse for planning clinical services or evaluating harm. Policy debates should not use prevalence alone as a proxy for success or failure. Better outcomes include fewer preventable injuries, less youth exposure, accurate labeling, informed adult use, accessible treatment, and reduced smoke-related burden. How Strong Is This Evidence? Strong for Gallup’s national estimates and the wording of the reported behaviors because the organization provides dates, sample size, random-digit-dial methods, weighting context, and a margin of sampling error. Limited for clinical interpretation because the poll does not measure product potency, dose, frequency, indication, impairment, dependence, respiratory symptoms, or medical outcomes. Where This Paper Deserves Skepticism The phrase record high is accurate within Gallup’s trend, but the 17% estimate ties 2023 and carries a plus or minus 4-point sampling margin. Self-report, question wording, nonresponse, and the broad verb smoke also limit precision. Comparisons with cigarette use do not establish relative safety. What This Paper Does Not Show The survey does not show that cannabis caused cigarette smoking to decline, that all respondents used cannabis frequently, that smoking was medical, that edibles replaced inhalation, or that any route improved or worsened health. It also cannot diagnose [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) or establish intoxication, driving risk, workplace impairment, or product quality. How This Fits With the Broader Clinical Conversation Seventeen percent reported smoking marijuana, while 15% reported consuming edibles. These questions may capture overlapping groups, so the percentages should not be added to estimate total [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/). The contrast with cigarettes is culturally important, but clinical comparisons require exposure detail. Combusted cannabis and tobacco have different pharmacology, yet both smoke routes expose lungs to combustion products. Dr. Caplan’s Take *A prevalence number becomes clinically useful only after the next questions are asked. What product is being used, by which route, at what dose and frequency, for what goal, and with what effects on sleep, mood, breathing, cognition, driving, work, and relationships?* *The poll should make cannabis conversations more routine, not more moralizing. A calm history can identify helpful use, avoidable smoke exposure, poorly controlled symptoms, escalating patterns, tobacco co-use, or impairment without assuming that every person represented by the 17% has the same experience.* What a Careful Reader Should Take Away Cannabis smoking is common enough to justify routine, specific clinical questions, while the poll itself says nothing about an individual’s benefit or harm. Evidence Interpretation Guide Table of Contents - [How to Read the Gallup Cannabis Numbers](#How_to_Read_the_Gallup_Cannabis_Numbers)[Four distinctions that matter](#Four_distinctions_that_matter) - [What a Record Cannabis-Smoking Estimate Means From Eight Perspectives](#What_a_Record_Cannabis-Smoking_Estimate_Means_From_Eight_Perspectives)[Turn a Headline Into a Personal Inventory](#Turn_a_Headline_Into_a_Personal_Inventory) - [Replace the Binary Cannabis Question](#Replace_the_Binary_Cannabis_Question) - [Discuss Function Without Turning Prevalence Into Permission](#Discuss_Function_Without_Turning_Prevalence_Into_Permission) - [Do Not Confuse Lower Cigarette Use With Harmless Smoke](#Do_Not_Confuse_Lower_Cigarette_Use_With_Harmless_Smoke) - [Build Surveillance Beyond a Single Percentage](#Build_Surveillance_Beyond_a_Single_Percentage) - [Judge Regulation by Outcomes, Not Popularity](#Judge_Regulation_by_Outcomes_Not_Popularity) - [Read the Record High With Its Error Bars](#Read_the_Record_High_With_Its_Error_Bars) - [Ask What the Trend Cannot Explain](#Ask_What_the_Trend_Cannot_Explain) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) ## How to Read the Gallup Cannabis Numbers This is a national behavior survey, not a clinical outcome study. Four distinctions keep the findings proportionate. ### Four distinctions that matter **Prevalence versus frequency**Reporting that one smokes marijuana does not reveal whether use is daily, monthly, or rare. **Route versus dose**Smoking and edibles identify broad routes but not product potency, amount consumed, or cumulative exposure. **Trend versus cause**A change over time does not identify which legal, cultural, commercial, or health factors produced it. **Population versus person**A national percentage cannot determine whether an individual’s use is beneficial, harmful, or disordered. The Public Health Question Can future surveys connect route and frequency with impairment, respiratory symptoms, medical purpose, and access to care? The Patient Question What does my route, dose, frequency, and response say about my own risk and goals? The Bottom Line Use the survey to improve the questions asked, not to substitute for individual assessment. CED Perspective Lens ## What a Record Cannabis-Smoking Estimate Means From Eight Perspectives The same prevalence number raises different questions about care, safety, surveillance, and policy Lens Overview Gallup’s estimate is most useful when readers separate population description from individual judgment and ask what additional information each audience needs. #### Turn a Headline Into a Personal Inventory A patient faces a more specific question than whether cannabis smoking is common: what is being used, how often, for what goal, and with what effect? The Gallup estimate can normalize an honest conversation, but it cannot determine whether use is helping symptoms, creating impairment, or exposing the lungs to avoidable smoke. A practical inventory includes route, product, THC and CBD content, dose, timing, tobacco or alcohol co-use, cough, mood, sleep, driving, and work demands. The boundary is important: being part of a common behavior does not make a particular pattern medically appropriate or unsafe by definition. Lens takeaway Use the national trend as permission to ask better personal questions, not as a verdict on your own use. #### Replace the Binary Cannabis Question Clinicians face a documentation problem when an intake form asks only whether a patient uses cannabis. Gallup separately measured smoking and edibles, illustrating that route changes the clinical conversation. Smoking raises combustion and respiratory questions, while oral products raise delayed-onset, prolonged-effect, and redosing questions. The practical implication is a structured but nonjudgmental history that covers route, dose, frequency, indication, effect, impairment, tobacco exposure, and safety-sensitive activities. The survey cannot establish a screening interval or diagnosis, and a positive response should not trigger an assumption of misuse. Lens takeaway Routine care should document route and pattern because a yes-or-no cannabis field is clinically incomplete. #### Discuss Function Without Turning Prevalence Into Permission Families may read a record-high estimate as reassurance that [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) is ordinary or as evidence of a worsening crisis. Neither interpretation follows from the poll. The useful question is whether a person’s pattern affects attention, mood, breathing, finances, caregiving, driving, school, work, or relationships. A concrete conversation focuses on observed effects, product storage, route, timing, and shared safety expectations rather than labels. The boundary is that family concern cannot diagnose dependence, while social acceptance cannot rule it out. Persistent conflict, impaired control, withdrawal, or risky use deserves clinical assessment. Lens takeaway Focus family conversations on function and safety because prevalence alone neither excuses nor diagnoses a problem. #### Do Not Confuse Lower Cigarette Use With Harmless Smoke Respiratory clinicians face a tempting but flawed comparison: cannabis smoking now exceeds cigarette smoking in Gallup’s estimate, while cigarette use is historically low. The poll measures reported behavior, not smoke exposure, inhalation technique, symptoms, lung function, or disease. The practical implication is to ask separately about joints, pipes, blunts, vaping, tobacco, cough, wheeze, and exercise tolerance. Reduced cigarette prevalence is an important public-health achievement, but it does not establish that cannabis smoke is benign or quantify the relative risk of the two exposures. Lens takeaway Treat cannabis smoke as a distinct respiratory exposure and avoid inferring safety from the decline in cigarette smoking. #### Build Surveillance Beyond a Single Percentage Public-health officials need to know whether rising self-reported smoking reflects occasional use, frequent use, medical use, co-use, or changing willingness to disclose. Gallup’s stable trend question is valuable, but it cannot answer those service-planning questions by itself. Future surveillance should preserve comparable wording while adding route, frequency, potency, age of initiation, impairment, respiratory symptoms, treatment need, and product source. The counterweight is respondent burden: longer questionnaires can reduce completion and comparability. Linked surveys may be more realistic than loading every measure into one poll. Lens takeaway Keep the stable trend measure, then pair it with deeper surveillance that can guide prevention and care. #### Judge Regulation by Outcomes, Not Popularity Policymakers face competing claims that higher prevalence proves legalization has succeeded or failed. Gallup’s survey supports neither conclusion because it does not compare policy regimes, measure causal exposure, or track health and safety outcomes. A more useful policy dashboard includes youth access, [impaired driving](https://cedclinic.com/cannabis-impairment-detection-driving-safety/), poison-center events, product testing, labeling accuracy, treatment availability, smoke exposure, equity, and adult knowledge. Adult prevalence belongs on that dashboard, but it should not dominate it. Common behavior still requires safeguards, and uncommon harm can still merit focused intervention. Lens takeaway Use prevalence as one policy indicator among many, with outcomes and implementation carrying more weight than symbolism. #### Read the Record High With Its Error Bars A skeptical reader should note that 17% ties the 2023 result rather than surpassing it. Gallup reports a plus or minus 4.0 percentage-point margin for the total sample, while subgroup estimates carry greater uncertainty. Question wording, self-report, and nonresponse can add error beyond sampling. That does not make the survey useless. A consistent measure across years can reveal a broad shift even when adjacent estimates overlap. The defensible judgment is that reported marijuana smoking is far above 2013 and remains near Gallup’s observed high, not that a precise one-year surge has been proven. Lens takeaway The long-term rise is clearer than any claim of a precise year-to-year jump in 2026. #### Ask What the Trend Cannot Explain Researchers face several unanswered questions: whether smoking and edible use overlap, how frequently each route is used, why respondents use cannabis, and whether changing disclosure contributes to the trend. The public report provides subgroup estimates but does not turn those cross-sectional differences into causal findings. A concrete next step is to connect repeated route measures with longitudinal or linked health data while protecting privacy. Even then, confounding and changing products will complicate interpretation. The value of Gallup’s series is a consistent population signal that can generate questions, not a substitute for exposure measurement or clinical epidemiology. Lens takeaway Treat the poll as a durable surveillance signal that identifies research needs rather than resolving clinical causation. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Gallup+Finds+Cannabis+Smoking+at+a+Record+High+in+2026&url=https%3A%2F%2Fcedclinic.com%2Fgallup-cannabis-smoking-record-high-2026%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fgallup-cannabis-smoking-record-high-2026%2F) [BlueSky](https://bsky.app/intent/compose?text=Gallup+Finds+Cannabis+Smoking+at+a+Record+High+in+2026%20https%3A%2F%2Fcedclinic.com%2Fgallup-cannabis-smoking-record-high-2026%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [U.S. Marijuana Smoking at Record High, Cigarettes at Low](https://news.gallup.com/poll/713645/marijuana-smoking-record-high-cigarettes-low.aspx) Related Reading at CED Clinic Continue exploring the evidence [Cannabis-Tobacco Co-Use and Respiratory Health](https://cedclinic.com/modes-of-cannabis-administration-cannabis-and-tobacco-co-use-and-associations/) Route-specific context on combustible use, tobacco co-use, and reported respiratory symptoms. [Read the route evidence](https://cedclinic.com/modes-of-cannabis-administration-cannabis-and-tobacco-co-use-and-associations/) [Cannabis Use Disorder in the Era of Legalization](https://cedclinic.com/cannabis-use-disorder-treatment-systems-legalization/) [Clinical context](https://cedclinic.com/cannabis-hyperemesis-syndrome-treatment-insights-2026/) for screening, withdrawal, treatment access, and avoiding stigma. [Review the clinical context](https://cedclinic.com/cannabis-use-disorder-treatment-systems-legalization/) [Medical Cannabis Use and Frequency in U.S. Adults](https://cedclinic.com/medical-cannabis-use-frequency-epidemiology/) National panel evidence separating medical status, age, and frequency among adult users. [Compare the population data](https://cedclinic.com/medical-cannabis-use-frequency-epidemiology/) ## Frequently Asked Questions What percentage of U.S. adults told Gallup they smoke marijuana in 2026? Seventeen percent, tying Gallup’s 2023 record high for this question. How many adults said they consume marijuana edibles? Fifteen percent of U.S. adults said they consume marijuana edibles. Can the smoking and edible percentages be added together? No. The groups may overlap because one respondent can use both routes. How large was the Gallup survey? Gallup reported telephone interviews with a random sample of 1,200 adults across all 50 states and the District of Columbia. What was the margin of sampling error? Gallup reported plus or minus 4.0 percentage points for results based on the total sample at the 95% confidence level. Does the poll show that cannabis smoking is safe? No. It measures self-reported behavior and does not assess dose, respiratory outcomes, impairment, dependence, or other health effects. Does the poll show cannabis caused cigarette smoking to decline? No. The two trends appear together, but the survey does not test whether one caused the other. Why should clinicians ask about route? Smoking, vaping, and oral products have different onset, duration, dosing, respiratory, and impairment considerations. Does reporting cannabis smoking diagnose [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/)? No. Diagnosis requires evidence about impaired control, consequences, tolerance, withdrawal, and other clinical criteria. What is the practical takeaway for patients? Discuss route, dose, frequency, goals, benefits, adverse effects, tobacco co-use, and safety-sensitive activities with a clinician. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).